New mRNA vaccine targets Epstein-Barr virus in first human trial
NCT ID NCT07557602
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is linked to some cancers, so a successful vaccine could have a big impact.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VXCO-102 (mRNA vaccine targeting Epstein-Barr virus)
What this could lead to
If successful, this could pave the way for a vaccine to prevent EBV infection, which is linked to mononucleosis and certain cancers.
What could go wrong
This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety, not effectiveness. The vaccine may not produce a strong immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
Herston, Queensland, 4006, Australia